Daily Cardiology Research Analysis
Organized, multidisciplinary atrial fibrillation services reduce all-cause mortality versus usual care, supporting system-level redesign. Long-term follow-up after TAVI shows low structural valve deterioration in survivors, with a signal favoring self-expanding devices. The new PREVENT risk equations demonstrate better calibration than PCE in UK Biobank despite similar discrimination, informing primary prevention risk assessment.
Summary
Organized, multidisciplinary atrial fibrillation services reduce all-cause mortality versus usual care, supporting system-level redesign. Long-term follow-up after TAVI shows low structural valve deterioration in survivors, with a signal favoring self-expanding devices. The new PREVENT risk equations demonstrate better calibration than PCE in UK Biobank despite similar discrimination, informing primary prevention risk assessment.
Research Themes
- Care delivery models in atrial fibrillation
- Long-term durability after transcatheter aortic valve implantation
- Cardiovascular risk prediction model performance and calibration
Selected Articles
1. Clinical service organisation for adults with atrial fibrillation: Cochrane systematic review and meta-analysis.
Across eight randomized trials (n=8205), organized AF care (collaborative/multidisciplinary/virtual) reduced all-cause mortality (RR 0.64) and cardiovascular hospitalizations (RR 0.83) versus usual care. Effects on all-cause hospitalization were minimal and cardiovascular mortality effects were uncertain.
Impact: Cochrane-grade evidence shows service organization alone can lower mortality in AF, a highly prevalent condition, providing a pragmatic, scalable intervention beyond pharmacotherapy or procedures.
Clinical Implications: Health systems should implement coordinated AF services (multidisciplinary clinics, virtual care pathways, mHealth-enabled follow-up) to reduce mortality and cardiovascular hospitalizations, while standardizing metrics to compare models.
Key Findings
- Organized AF services reduced all-cause mortality versus usual care (RR 0.64, 95% CI 0.46–0.89; moderate certainty).
- Cardiovascular hospitalizations were reduced (RR 0.83, 95% CI 0.71–0.96; high certainty).
- Little to no effect on all-cause hospitalization (RR 0.94, 95% CI 0.88–1.02) and uncertain effect on cardiovascular mortality.
- Thromboembolic and major cerebrovascular event reductions were minimal; minor cerebrovascular events were not reported.
Methodological Strengths
- Cochrane methodology with pre-registered review and comprehensive database search.
- Inclusion limited to randomized controlled trials with certainty grading.
Limitations
- Heterogeneity in care model designs and implementation intensity across trials.
- Limited reporting for some outcomes (e.g., minor cerebrovascular events) and uncertainty for cardiovascular mortality.
Future Directions: Head-to-head comparisons of care models, integration of mHealth at scale, cost-effectiveness analyses, and evaluation of equity impacts and implementation fidelity.
AIMS: This study aims to assess the effects of organized clinical service delivery models for atrial fibrillation (AF) on all-cause mortality and hospitalization, as well as cardiovascular outcomes, thromboembolic events, bleeding complications, quality of life, symptom burden, healthcare costs, and length of hospital stay. METHODS AND RESULTS: A systematic search was conducted across several databases, including Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and CINAHL, and clinical trial registries. Randomized controlled trials involving adults (≥18 years) with any type of AF were included. Primary outcomes were all-cause mortality and all-cause hospitalization. Secondary outcomes included cardiovascular mortality and hospitalization, AF-related emergency department visits, thromboembolic and bleeding events, quality of life, symptom burden, cost of intervention, and length of hospital stay. Eight studies (8205 participants) investigating collaborative, multidisciplinary, or virtual care models for AF were included. The mean age of participants ranged from 60 to 73 years. Organized AF clinical services likely resulted in a substantial reduction in all-cause mortality [risk ratio (RR) 0.64, 95% confidence interval (CI) 0.46-0.89; moderate certainty] and cardiovascular hospitalization (RR 0.83, 95% CI 0.71-0.96; high certainty) compared with usual care. However, these services probably made little to no difference to all-cause hospitalization (RR 0.94, 95% CI 0.88-1.02; moderate certainty) and may not reduce cardiovascular mortality (RR 0.64, 95% CI 0.35-1.19; low certainty). The effect on thromboembolic complications and major cerebrovascular events appeared minimal. Minor cerebrovascular events were not reported in any of the included studies. CONCLUSION: Moderate certainty evidence suggests that organized clinical services for AF likely lead to a large decrease in all-cause mortality but probably have minimal impact on all-cause hospitalization. Whilst cardiovascular hospitalizations were reduced, the effect on cardiovascular mortality remains uncertain. Further research is needed to compare different care organization models and to confirm findings for inconclusive outcomes, particularly regarding the role of mHealth in AF management. The findings highlight the importance of coordinated care through collaborative, multidisciplinary, and virtual approaches. REGISTRATION: Cochrane Database for Systematic Reviews (2019): https://doi.org/10.1002/14651858.CD013408. Citation to published full Cochrane review: Ferguson C, Shaikh F, Allida SM, Hendriks J, Gallagher C, Bajorek BV, Donkor A, Inglis SC. Clinical service organisation for adults with atrial fibrillation. Cochrane Database of Systematic Reviews 2024, Issue 7, Art. No.: CD013408. https://doi.org/10.1002/14651858.CD013408.pub2. Citation to published Cochrane review protocol: Ferguson C, Hendriks J, Gallagher C, Bajorek BV, Inglis SC. 2019. Clinical Service organisation for adults with atrial fibrillation: Protocol - Intervention. 2019, Issue 8, Art No.: CD013408. https://doi.org/10.1002/14651858.CD013408.
2. Outcomes Beyond 10 Years After Transcatheter Aortic Valve Implantation in High-Risk Patients With Severe Aortic Valve Stenosis.
In a cohort of 1,825 high-risk early-era TAVI patients (2006–2012), 12-year mortality was high (92.8%), but among survivors with ≥9-year imaging, structural valve deterioration was infrequent (moderate 5.4%, severe 3.6%). Self-expanding valves showed fewer SVD events than balloon-expandable devices.
Impact: Provides rare, long-horizon data on TAVI durability using VARC-3 definitions and suggests potential device-related differences in structural valve deterioration.
Clinical Implications: Supports long-term surveillance strategies after TAVI and may inform device selection and counseling on durability; underscores need for consistent late imaging in survivors.
Key Findings
- Among 1,825 high-risk TAVI patients, 12-year mortality reached 92.8%.
- Cumulative structural valve deterioration at 12 years was 9.8% overall.
- In ≥9-year survivors with echocardiography (n=56), moderate SVD 5.4% and severe SVD 3.6%.
- Self-expanding valves had lower any SVD versus balloon-expandable (2.8% vs 20.0%, p=0.030).
Methodological Strengths
- Large single-center cohort with extended follow-up beyond 10 years.
- Standardized VARC-3 definitions for structural valve deterioration.
Limitations
- Survivor bias and limited echocardiographic follow-up in late survivors (n=56).
- Retrospective design and early-era devices limit generalizability to contemporary TAVI.
Future Directions: Prospective, multicenter late-imaging surveillance with device-specific analyses; real-world comparisons of contemporary self-expanding versus balloon-expandable platforms.
BACKGROUND: Limited data is available on long-term outcomes and valve durability measures of transcatheter aortic valve implantation (TAVI). AIMS: This study sought to assess clinical and echocardiographic outcomes of high-risk patients during the early experience of TAVI with a follow-up period extending beyond 10 years. METHODS: Patients were included who had undergone TAVI at the Heart Center Leipzig between 2006 and 2012. Valve durability measures including moderate and severe structural valve deterioration (SVD) were defined according to the updated standardized definitions of the Valve Academic Research Consortium 3 (VARC-3). RESULTS: A total of 1825 patients were included. The 12-year mortality rate was 92.8%. At 12 years post-TAVI, the cumulative incidence of SVD was 9.8% in the total population. Complete echocardiographic follow-up at ≥ 9 years was available for 56 patients. The median follow-up of this subgroup was 10.0 years. Moderate SVD was observed in three patients of the echocardiographic follow-up cohort (5.4%) and severe SVD in two patients (3.6%). Self-expanding (SE) transcatheter heart valves (THV) had a significantly lower rate of any SVD (2.8% vs 20.0%, p = 0.030) than balloon-expandable (BE) THV. CONCLUSION: Long-term mortality rates in high-risk patients treated with TAVI more than 10 years ago are substantial, which limits assessment of valve durability measures. In a subgroup of survivors beyond 9 years, the cumulative incidence of SVD was low.
3. Performance of PREVENT and pooled cohort equations for predicting 10-Year ASCVD risk in the UK Biobank.
In 368,125 UK Biobank participants free of CVD, PREVENT and PCE had nearly identical discrimination (C-statistics ~0.73 in women, ~0.69 in men), but PREVENT showed superior calibration across deciles. Findings inform selection of risk equations for primary prevention decisions.
Impact: Clarifies real-world performance of new PREVENT equations versus established PCE in a large external cohort, highlighting calibration advantages crucial for treatment thresholds.
Clinical Implications: Clinicians may prefer PREVENT for better calibration when estimating 10-year ASCVD risk, potentially improving statin allocation; local recalibration may still be needed given cohort demographics.
Key Findings
- PREVENT and PCE had similar discrimination (women C≈0.73; men C≈0.69) in UK Biobank.
- PREVENT demonstrated better calibration across risk deciles than PCE.
- Sex-stratified performance confirmed minimal differences in discrimination but calibration advantage for PREVENT.
- Implications for statin eligibility assessment via sensitivity/specificity analyses.
Methodological Strengths
- Very large external cohort with sex-stratified analyses.
- Comprehensive assessment of discrimination and calibration by deciles.
Limitations
- UK Biobank selection bias and predominantly White ancestry limit generalizability.
- Details of event adjudication and competing risks not described in abstract.
Future Directions: Validation across more diverse populations, local recalibration studies, and impact analyses on treatment decision-making and outcomes.
BACKGROUND: The Pooled Cohort Equations (PCE) were created in 2013 to assess ASCVD risk in primary prevention. In 2023 the American Heart Association published the PREVENT equations to assess the risk of cardiovascular disease in primary prevention. The comparative performance of PCE and PREVENT for predicting 10-year ASCVD risk has not been evaluated in an external large-scale epidemiologic cohort. METHODS: The study population includes participants of the UK Biobank who were free of clinical cardiovascular disease. 10-year ASCVD risk was calculated using the PCE and PREVENT equations. Harrel's C-Statistics and delta C-Statistics were calculated for males and females to evaluate risk discrimination. Predicted 10-year risks were divided into deciles as well as risk groups for each equation and stratified by sex to compare predicted risk versus observed risk within each risk group, with calibration slopes calculated by decile. Sensitivity and specificity were also analyzed to assess statin eligibility. RESULTS: The final cohort was 368,125 individuals ages 40-73 (mean age 56.2, 54.7 % female, 94.0 % white). The C-statistics for PCE were 0.729 (0.722-0.736) for females and 0.688 (0.683-0.693) for males; C-Statistics for PREVENT were 0.728 (0.721-0.735) for females and 0.687 (0.682-0.692) for males, with delta C-Statistics being 0.001 ( CONCLUSIONS: There is no significant difference in 10-year ASCVD risk discrimination between PCE and PREVENT equations. However, the PREVENT equations demonstrate better calibration in the UK Biobank.